Search Results
488 results found for "Cost-efficient medications https://simplemedrx.top"
- Anavex Reports Animal Study Results as Lead Alzheimer’s Compound Approaches Phase 1 Clinical Trials
Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Comments on Failure of Pfizer and Medivation’s Dimebon
(“ANAVEX”) (OTCBB: AVXL) today issued a statement following today’s announcement from Pfizer and Medivation Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Appoints Dr. Cameron Durrant Executive Chairman of the Board
Durrant is a medically trained MBA who has a unique entrepreneurial background coupled with major international Most recently, Dr. Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Contracts FORENAP Pharma for Pre-Clinical Trials of ANAVEX 2-73 in Alzheimer's Disease
We look forward to running a high-quality and cost-effective program as ANAVEX works to confirm its pre-clinical Platform involves the rational design of drug compounds that fulfill specific criteria based on unmet medical therapeutic areas are performed in a 72 highly monitored bed equipped centre, which is specifically dedicated For further Information: ANAVEX Research & Business Development Email: info@anavex.com Shareholder & Media
- Anavex Completes Scale-Up Manufacturing of ANAVEX 2-73 for Phase I AD Clinical Trials
Platform involves the rational design of drug compounds that fulfill specific criteria based on unmet medical Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- ANAVEX Appoints Dr. Hervé de Kegrohen as CEO to Lead Company Through Clinical Trials & Future Growth
Dr. de Kergrohen holds a Medical Degree from Université Louis Pasteur in Strasbourg and a MBA from INSEAD Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Appoints Leading Alzheimer’s Disease Expert Dr. Mark Smith to Scientific Advisory Board
Smith is recognized as one of the world’s most cited researchers in the fields of Alzheimer’s disease Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Scales Up Synthesis of ANAVEX 2-73 for Phase 1 Alzheimer’s Disease Study
Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Ground-Breaking Anti-Amnesic and Neuroprotective Effects of Alzheimer’s Compound ANAVEX 1-41
Neuropsychopharmacology is an international scientific journal and the official publication of the American Against Amyloid-beta (25-35)-Induced Toxicity in Mice,” can be viewed on the publication’s web site at http Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Presents Potent Neuroprotective Effects of ANAVEX 1-41 at Neuroscience 2008
Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Completes Successful Preclinical Studies on Lead Alzheimer’s Drug Candidate
Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
- Anavex Presents Neuroprotective Effects of ANAVEX 1-41 at the International Conference on AD 2008
Neuroprotection is the most important component necessary to attain long-term benefits in neurodegenerative Research & Business Development Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866
